2022-2029 年临床微生物学全球市场

市场动态

全球临床微生物学市场的增长受到某些因素的推动，例如传染病的上升和公众意识的提高。

在分子水平上了解慢性病和开发治疗解决方案的需求日益增长，预计将在预测期内推动市场发展，更多组织资助研发计划。

根据美国疾病控制和预防中心 (CDC) 的数据，2020 年美国将有大约 7,860 例新的结核病病例、大约 30,000 例莱姆病新病例和大约 30,000 例脑膜炎球菌病新病例。已註册 375 人。

同样，根据美国癌症协会的数据，2021 年美国将有大约 190 万例新诊断的癌症病例。因此，将实验室检测作为主要诊断工具之一的疾病的高流行率预计将在未来促进市场增长。埃博拉病毒和寨卡病毒等传染性病原体的爆发也导致传染病流行率上升。根据发表在《临床微生物学杂誌》上的一篇文章，在医学和微生物学实验室中，处理和解释样本和标本的训练有素和熟练的专业人员供不应求。此外，美国医学实验室技术人员培训项目的数量和毕业学生的数量正在直线下降。

在高收入国家加紧努力抗击医院感染的同时，低收入和中等收入国家也意识到了这一威胁。预计自动化系统和创新设计的引入将在预测期内增加市场竞争并改变市场动态。这一因素正在推动预测期内的市场增长。

世界卫生组织 (WHO) 在埃塞俄比亚、布基纳法索、尼日利亚、阿尔及利亚和塞内加尔等国家尤为活跃，这些国家的 HAI 发病率介于 2.5% 和 14.8% 之间。因此，这些国家对 HAI 诊断的需求不断增长。印度、斯里兰卡、巴基斯坦和不丹等国家也在积极参与 HAI 宣传计划。印度和中国预计将成为未来推动对 HAI 诊断设备和测试需求的主要国家。这一因素也推动了预测期内的市场增长。

同样，诊断实验室链的整合和公众意识的提高等因素也推动了市场的增长。新兴市场预计将超过美国和欧洲国家。这主要是由于大型连锁医院在大城市开设新中心以及政府支出增加。

缺乏对微生物检测方法的报销可能会阻碍市场增长

但是，目前在印度、中国以及中东和非洲的其他新兴经济体等目标患者群体众多的国家/地区，临床微生物检测程序的报销不足。这是患者和医疗保健专业人员对临床微生物学产品的偏好的主要限制因素。这将对预测期内的市场增长产生负面影响，因为它将直接影响采用高价临床微生物产品。

COVID-19 影响分析

最近爆发的 COVID-19 大流行对市场的增长产生了负面影响，因为实验室忙于 COVID-19 测试并停止了所有其他测试。这一因素将阻碍预测期内的市场增长。

行业分析

全球临床微生物学市场根据波特五力分析、供应链分析、监管分析和定价分析等各种行业因素对市场进行了深入分析。

全球临床微生物学市场报告提供大约 40 多个市场数据表、45 多个图表和 180 页结构。

内容

第1章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

• 按产品类型划分的市场细分
• 按应用划分的市场细分
• 按地区划分的市场细分

第 4 章市场动态

• 市场影响因素
  • 驱动程序
    • 感染增加
    • 提高社会认可度
  • 限制因素
    • 在许多国家/地区，临床微生物学费用并未全额报销。
• 影响分析
• 商机

第5章行业分析

• 波特五力分析
• 供应链分析
• 监管分析
• 定价分析
• 产品分析
• 售后服务分析

第 6 章按产品类型分析

• 试剂
• 实验室仪器
  • 孵化器
  • 克过滤器
  • 菌落计数器
  • 高压灭菌器
  • 培养皿灌装机
• 自动培养系统
  • 微生物检测设备
  • 分子生物诊断设备
  • 显微镜
  • 质谱仪

第 7 章按应用程序

• 呼吸系统疾病
• 血液感染
• 消化系统疾病
• 其他

第 8 章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲地区
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第 9 章竞争格局

• 竞争场景
• 市场情况/份额分析
• 併购分析

第 10 章公司简介

• 生物梅里埃公司
  • 公司简介
  • 产品组合和描述
  • 主要发展状况
  • 财务摘要
• Danaher Corporation, Becton
• Dickinson and Company
• Abbott Laboratories
• Bio-Rad Laboratories, Inc
• , F. Hoffmann-La Roche AG
• Bruker Corporation
• Hologic, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.（*List is not exhaustive）

第11章 DataM

Market Overview

Clinical microbiology market size was valued at US$ 3.9 billion in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 6.5% during the forecast period (2022-2029).

Clinical microbiology focuses on all aspects of patient infections from testing samples to identifying bacterial, viral, fungal, and parasitic agents that are contributing to the infectious process, determining the susceptibility of microorganisms to various antimicrobial agents, and reporting the results to healthcare providers.

The adaptation of microbiological techniques to the study of the etiological agents of infectious disease. Clinical microbiology determines the nature of the infectious disease and tests the ability of various antibiotics to inhibit or kill the isolated microorganisms. In addition to bacteriology, a contemporary clinical microbiologist is responsible for a wide range of microscopic and cultural studies in mycology, parasitology, and virology. The clinical microbiology is often the most competent person available to determine the nature and extent of hospital-acquired infections, as well as public-health problems that affect both the hospital and the community.

Market Dynamics

The global clinical microbiology market growth driven by certain factors such as by rise in infectious diseases, increase in public awareness are among the key factors driving the market growth.

Increasing need to understand chronic diseases at a molecular level and develop therapeutic solutions to encourage these organizations to fund research and development programs., is expected to drive the market during the forecast period

According to the Centers for Disease Control and Prevention (CDC), around 7860 new cases of tuberculosis, 30,000 new cases of Lyme disease, and 375 new cases of meningococcal disease were registered in the U.S. in 2020.

Similarly, according to the American Cancer Society, around 1.9 million new cases of cancer were diagnosed in the U.S. in 2021. Thus, the high prevalence of diseases where clinical tests are used as one of the major diagnostic tools is expected to augment market growth in the future. Sudden outbreaks of Ebola, Zika, and other contagious pathogens are also contributing to the rising prevalence of infectious diseases. As per an article published in the Journal of Clinical Microbiology, there is a shortage of trained and skilled professionals in medical and microbiological laboratories for processing and interpreting samples and specimens. Moreover, there has been a steep decline in the number of medical laboratory training programs and students graduating from such programs in the U.S.

As high-income countries are stepping up their pursuit of countering hospital-acquired infections, middle- and low-income countries are recognizing the threat. The introduction of automated systems and innovative designs is expected to intensify market competition and change market dynamics over the forecast period. This factor is driving the growth of the market in the forecast period.

The World Health Organization (WHO) is particularly active in countries such as Ethiopia, Burkina Faso, Nigeria, Algeria, and Senegal, where the occurrence of HAIs ranged between 2.5% and 14.8%. This has led to increased demand for HAI diagnostics in these countries. Countries such as India, Sri Lanka, Pakistan, and Bhutan are also actively participating in HAI awareness programs. India and China are projected to be the main countries driving demand for HAI diagnostics instruments and tests in the future. This factor is also driving the growth of the market in the forecast period.

Similarly, factors like the consolidation of diagnostic laboratory chains and the increase in public awareness are driving the growth of the market. The emerging countries are expected to outperform the U.S. and European countries. This is mainly due to the increase in the major hospital chains opening new centers in major cities as well as an increase in government expenditure.

Lack of reimbursement of microbiology testing procedures are likely to hamper the market growth

However, Clinical microbiology testing procedures are not adequately reimbursed across several countries such as India, China, and other emerging countries in the Middle East and Africa, which have a high target patient population base. This is a major factor that limits the preference for clinical microbiology products among patients and healthcare professionals. This directly affects the adoption of premium-priced clinical microbiology products, thereby negatively affecting their market growth in the forecast period.

COVID-19 Impact Analysis

The recent outbreak of the COVID-19 pandemic is negatively affecting the growth of the market as the laboratories are busy with the COVID-19 test which has halted all other tests. This factor will hinder the growth of the market in the forecast period.

Industry Analysis

The global clinical microbiology market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, supply chain analysis, regulatory analysis, pricing analysis etc.

Segment Analysis

The laboratory instruments segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The global clinical microbiology market is segmented based on product type by laboratory instruments which are further sub-segmented into incubators, gram strainers, bacterial colony counters, autoclave sterilizers, petri dish fillers, and automated culture systems which is further sub-segmented into microbiology analyzers, molecular diagnostic instruments, microscopes, mass spectrometers, and reagents. The reagents segment held the largest market share. Factors such as the higher cost of specialized kits and constant repeat purchase are expected to drive the segment over the forecast period. A reagent s a substance or compound added to a system to cause a chemical reaction, or added to test if a reaction occurs. The importance of reagents will continue to outstrip supplies in many places as the race for safe and effective vaccines and treatment. A reagent may be used to tell whether or not a specific chemical substance is present by causing a reaction to occur with it.

The laboratory instruments segment is expected to have a positive market. Laboratories require a variety of equipment and consumables to perform tests and research activities. These are found in different types of laboratories such as research labs, clinical diagnostic labs, pathology labs, microbiology labs, educational labs, etc. to carry out research, scientific experiments, and execute analyses of different scientific materials.

It is estimated that the laboratory instrument segment is expected to witness significant growth over the forecast period, owing to technological advancements in the field of laboratory equipment, an increase in the number of clinical diagnostic procedures, and a rise in private & public healthcare investments. Besides, favorable insurance policies related to laboratory equipment further supplement the market growth. Furthermore, an increase in research related to life science and biotechnology boosts the laboratory instruments segment

Increasing chronic diseases such as chronic respiratory diseases, cardiovascular diseases, and diabetes, and increasing incidence of lifestyle diseases such as heart disease, obesity, atherosclerosis and hereditary diseases such as hemophilia, Down's syndrome, cystic fibrosis, and sickle cell anemia are leading to the increasing demand of laboratory equipment to bring innovative technologies in the market. According to the World Health Organization (WHO), the non-communicable disease leads to cause 40 million deaths each year, which is equivalent to 70% of all deaths worldwide. Cardiovascular diseases account for most of NCD mortality (17.7 million) annually, followed by cancer (8.8 million), respiratory disease (3.9 million), and diabetes (1.6 million). Thus, these factors will drive the growth of the market in the forecast period.

Further, the market is also classified based on application as respiratory diseases, bloodstream infections, gastrointestinal diseases, and others. The respiratory diseases segment is held the largest market share. The rise in prevalence of respiratory infectious diseases, such as Coronavirus diseases, MERS, chronic obstructive pulmonary disease, tuberculosis, pertussis, and influenza, is projected to drive the segment.

According to data published in January 2020, 2519 laboratory-conformed cases of Middle East respiratory syndrome (MERS), were reported, which includes 866 associated deaths globally. The majority of cases reported were from Saudi Arabia (2121 cases), including 788 related deaths with a higher fatality rate of 37.1%.

Moreover, the emergence of the COVID 19 pandemic has driven the segment. According to statistics, as of April 2020, there were around 3.45 million cases of COVID-19 globally, which drives the respiratory diseases segment. This factor will drive the growth of the market in the forecast period.

Geographical Analysis

North America region holds the largest market share of the global clinical microbiology market

North America dominated the global surgical glue market and is expected to grow at the highest CAGR during the forecast period due to an increase in the burden of COVID-19, well-developed health care infrastructure, and increasing prevalence of chronic obstructive pulmonary diseases, flu diseases, whooping cough, and other respiratory infections. This is anticipated to augment the Respiratory infectious disease treatment market in the region. COPD is considered to be the third-leading cause of death in the U.S., and the fourth-leading cause of death across the world. According to an article published on Very well Health, COPD affects around 11 million people in the U.S. and occurs in people over the age of 40. These statistics drive the demand for the treatment of respiratory infectious diseases. This factor will drive the growth of the market in the region.

Competitive Landscape

The global clinical microbiology market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market bioMerieux SA, Danaher Corporation, Becton, Dickinson and Company, Abbott Laboratories, Bio-Rad Laboratories, Inc, F. Hoffmann-La Roche AG, Bruker Corporation, Hologic, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc. are the leading market players with significant market share.

Key Companies to Watch

Bio-Rad Laboratories

Overview: Bio-Rad Laboratories, Inc. is an American company that continued to produce innovative and useful products in the healthcare industry that assist life science researchers in accelerating the discovery process, and medical diagnostic labs obtain faster better results.

Product Portfolio: DC Protein Assay Reagents Package- Reagent pack for colorimetric assays, includes 250 ml alkaline copper tartrate, 2 L dilute Folin reagent, 5 ml surfactant solution; 450 assays.

The global clinical microbiology market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Product Type
• 3.2. Market Snippet by Application
• 3.3. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. A rise in infectious diseases
    • 4.1.1.2. Increase in public awareness
  • 4.1.2. Restraints
    • 4.1.2.1. Clinical microbiology testing procedures are not adequately reimbursed across a number of countries
• 4.2. Impact Analysis
• 4.3. Opportunity

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis
• 5.4. Pricing Analysis
• 5.5. Product Analysis
• 5.6. Post Sales Services Analysis

6. By Product Type

• 6.1. Introduction
• 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
• 6.3. Market Attractiveness Index, By Product Type
  • 6.3.1. Reagents *
    • 6.3.1.1. Introduction
    • 6.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2020-2028
  • 6.3.2. Laboratory Instruments
    • 6.3.2.1. Incubators,
    • 6.3.2.2. Gram strainers
    • 6.3.2.3. Bacterial colony counters
    • 6.3.2.4. Autoclave sterilizers
    • 6.3.2.5. Petri dish fillers
  • 6.3.3. Automated Culture Systems
    • 6.3.3.1. Microbiology Analyzers
    • 6.3.3.2. Molecular diagnostic instruments
    • 6.3.3.3. Microscopes
    • 6.3.3.4. Mass Spectrometers

7. By Application

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
• 7.3. Market Attractiveness Index, By Application
  • 7.3.1. Respiratory Diseases
    • 7.3.1.1. Introduction
    • 7.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3.2. Bloodstream Infections,
  • 7.3.3. Gastrointestinal Diseases
  • 7.3.4. Others

8. By Region

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
• 8.3. Market Attractiveness Index, By Region
• 8.4. North America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. The U.S.
    • 8.4.5.2. Canada
    • 8.4.5.3. Mexico
• 8.5. Europe
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. Germany
    • 8.5.5.2. The U.K.
    • 8.5.5.3. France
    • 8.5.5.4. Rest of Europe
• 8.6. South America
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.6.5.1. Brazil
    • 8.6.5.2. Argentina
    • 8.6.5.3. Rest of South America
• 8.7. Asia Pacific
  • 8.7.1. Introduction
  • 8.7.2. Key Region-Specific Dynamics
  • 8.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 8.7.5.1. China
    • 8.7.5.2. India
    • 8.7.5.3. Japan
    • 8.7.5.4. Australia
    • 8.7.5.5. Rest of Asia Pacific
• 8.8. The Middle East and Africa
  • 8.8.1. Introduction
  • 8.8.2. Key Region-Specific Dynamics
  • 8.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 8.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

• 10.1. bioMerieux SA*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Key Developments
  • 10.1.4. Financial Overview
• 10.2. Danaher Corporation, Becton
• 10.3. Dickinson and Company
• 10.4. Abbott Laboratories
• 10.5. Bio-Rad Laboratories, Inc
• 10.6. , F. Hoffmann-La Roche AG
• 10.7. Bruker Corporation
• 10.8. Hologic, Inc.
• 10.9. QIAGEN N.V.
• 10.10. Thermo Fisher Scientific Inc. (*List is not exhaustive)

11. DataM Intelligence

• 11.1. Appendix
• 11.2. About Us and Services
• 11.3. Contact Us